PareCOXib 是一种有效的选择性 COX-2 抑制剂，是 ValdeCOXib 的前药。

Parecoxib is an effective and selective COX-2 inhibitor.

Parecoxib, a selected cyclooxygenase-2 inhibitor, ameliorates neurologic deficits in the behavior studies and brain damage, including neuronal death, and brain edema in the MCP-1 and NeuN immunostaining in rats subjected to SAH(Subarachnoid Hemorrhage). Parecoxib is able to reduce early COX2 expression via inhibiting cJNK (p55) expression (dose-dependently), reduce IL-1β, IL-6 and MCP-1( at 2000 ug/kg/day at the time point of 24hr and 72hr after the induction of SAH), IL-8 (of the dosage of 2000 ug/kg/day at 24hr after the induction of SAH), and also reduce cleaved caspase-1 (at 1000 and 2000 ug/kg/day) and Caspase-9a (at 2000 ug/kg/day). Parecoxib reduces the NMDAR-1, and NMDAR-2a (at 1000 and 2000 ug/kg) after the induction of SAH[2].

198470-84-7

C19H18N2O4S

370.42

SC 69124;帕瑞昔布;Valus-P;Vorth-P

Ethanol:2 mg/mL (5.4 mM)
H2O:<1 mgml
DMSO:69 mg/mL (186.3 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years